SlideShare a Scribd company logo
1 of 72
Download to read offline
HPV NATURAL HISTORY AND HPV
TESTING
Mario Sideri
Unità Ginecologia Preventiva
Istituto Europeo di Oncologia, Milano
Italian HPV Study Group (IHSG)
What’s new?
In the last 30 years the causal association
between HPV infection and cervical cancer
has been demonstrated
papillomavirus
The Nobel Prize in Physiology or Medicine 2008
Harald Zur Hausen for his discovery of human
Papilloma viruses causing cervical cancer
Vaccination Population at
risk (screening)
Detection & Intervention
(pre-cancer elimination)
OLD STRATEGYNEW STRATEGY
Papillomavirus is known from decades.
However only in the recent years we have
recognized the wide diffusion and the benign
meaning of HPV infection
What is HPV?
Human Papillomavirus
 Papillomavirus are species specific viruses
 HPV are very common viruses and are
present in almost all the species of
mammalians and birds
 More than 100 HPV types have been
described in humans
 Human PV infect the skin and mucous
membranes where they can cause typical
benign proliferations as warts and papillomas
Papillomavirus
De Villiers et al., Virology (2004)
 HPV infection causes in some
instances microproliferations not visible
with the naked eye
 HPV tends to prersist for long periods
of time, often as latent infection
 Some HPV associated lesions can
evolve into malignant neoplasia
Papillomavirus
De Villiers et al., Virology (2004)
HPV Infection
Langerhans
cells
Dendritic
cells
Dermis
Micro-wound
Epidermis
Draining lymphatics
Basement
membrane
CD 16
 90% of young women acquires the
virus with the beginning of sexual
intercourses
 Most of them become negative after
6-18 months of transient infection
 Only about 10% of young women
become persistently infected with HPV
for a longer period of time
HPV
natural history
 less than 30% of persitently infected
women develops a CIN lesion
 the vast majority of CIN clears
spontaneously
 some CIN persist, but even most of
persistent CIN3 will never become
cancer
HPV
natural history
In this way, the almost ubiquitary HPV
infection, very rarely ends up into cervical
cancer.
Conversely, the association of HPV
infection with cervical cancer offers unique
opportunities of cancer prevention
HPV and Cervical Cancer
 553 college students (mean age 19)
 HPV test and pap smear every 4 months for
5 years
 mean follow up 41.2 months
HPV natural history:
Seattle Study
Winer et al., Am J Epidemiol (2003)
 19.7% was HPV DNA positive at
enrollment
 During two years follow up 39% of
women negative at enrollment became
HPV DNA positive
 High risk HPV were found more
frequently, types 16,18,51,56,33,35,39
Winer et al., Am J Epidemiol (2003)
HPV natural history:
Seattle Study
Winer et al., Am J Epidemiol (2003)
 60 adolescents (14-17) were followed for a
mean time of 26 months
 Every three months were evaluated for HPV
infection
 In addition a weekly self sampling for HPV
was performed for a time lenght up to 15
weeks
Brown et al., J Infect Dis (2005)
HPV natural history:
Adolescent study
Timing HPV overall HPV oncogenic
Enrollment 28% 22%
Last visit 40% 37%
At least once* 82% 77%
Brown et al., J Infect Dis (2005)
* At least two positive samples
HPV natural history:
Adolescent study
Only 3 girls were always negative to vaginal
HPV testing
 All referred to be virgins
Brown et al., J Infect Dis (2005)
HPV natural history:
Adolescent study
 HPV detectability rarely persist for more
than 24 months
 in more than 90% of the cases HPV
becomes undetectable within 24 months
HPV
Natural history
Detectable HPV
Author Age 6 12 24
__________________________________
Woodman 20 24 4 <1
Mosicki 20 50 30 10
Ho 20 30 9
% persistent HPV
infection in months
 persistent HPV infection may cause the
development of invasive cervical cancer in 10
to 15 years
 many known and unknown co-factors are
responsible for cancer develpoment
HPV
Natural history
 20.817 women with neagtive cytology at
baseline
 HPV test at enrollement
 Follow up for 10 years; endpoint CIN2-3
development
Natural history of HPV oncogenesis
Portland study
Kahn et al., JNCI (2005)
0%
5%
10%
15%
20%
25%
0,0 4,5 15,0 27,0 39,0 51,0 63,0 75,0 87,0 99,0 111,0 119,5
Follow-Up Time (months)
CumulativeIncidenceRateof≥CIN3
HPV16
+
HPV18
+
HPV
+
HPV+/
HPV16-
/18-
HPV
-
Kahn et al., JNCI (2005)
CIN3 develpoment during follow
up in relation to HPV status
ALL
HPV 16
Rodriguez et al., Proceedings of 24th International HPV Conference and Clinical Workshop, China 2007. Abstract
 HPV persistent infection can cause the
development of invasive cervical cancer in 10
to 15 years
 many co-factors are involved in the process
of cancer development
Natural history of HPV infection
Few studies addressed
in longitudinal studies
HPV status in sex
couples
HPV:
what we know in sex couples?
….In our current study, less than half
of the couples exhibited perfect HPV-
type specific concordance. More than
one third of couples had complete
discordance…..
Multivariate regression analysis.
Reporting a new sex partner or the same sex
partner or no sex partner was not significantly
associated with the risk of infection
reappearance.
HPV Clearance
HPV re-infection
(redection)
HPV infection is very common and is
not a disease
pre-cancer is a rare event
cancer is an exceptional event
HPV:
what we now know
HPV infection is very rarely
associated to cancer
development
However HPV is necessary for
cancer develpoment
HPV and Cervical Cancer
Cervical cancer screening
• Pap smear as primary screening test
• Identification of CIN3
• Elimination of CIN3 through excisional
conservative surgery
The historical strategy
Screening aim
To identify and eliminate this lesion
Vaccination Population at
risk (screening)
Detection & Intervention
(pre-cancer elimination)
USUAL STRATEGYNEW STRATEGY
Cervical cancer screening
• Testing the population for the
causative agent of cervical cancer
• Testing aimed to identifcation of CIN3
• Testing not aimed to detect infection
HPV TESTING
Cervical cancer screening
PROOF of PRINCIPLE
HPV TESTING
CERVICAL CANCER SCREENING IN INDIA
N = 131.476
Four arms randomized study:
•Control
•VIA
•Pap smear
•HPV test
HPV test
Pap smear
VIA
Control
Cervical cancer screening
known limitations of
cytology screening
PAP SMEAR
30
40
50
60
70
80
90
100
1971 1973 1975 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001
8
9
10
11
12
13
14
15
16
17
18
Incidence/100000
ScreeningCoverage(%)
Cervical cancer screening
Start of organised screening
Never pap smear 162 62%
Pos. pap & adequate
follow-up
29 11%
False negative pap 37 14%
Previous abnormal
smear*
34 13%
TOTAL 262 100%
Screening “failures”
italian data
Amadori A. Int J Gynecol Cancer 1998
262 invasive cancer cases, TR Romagna and Toscana (1986-93).
* Repeat smear not done, colposcopy not done, colposcopy done late,
negative colposcopies, negative biopsies,
CIN3 diagnosed with no further action.
Cause, n (%)
Kaiser
study1
Swedish
study2
No recent screen 464 (56%) 789 (64%)
Cytology detection
failure
263 (32%) 300 (24%)
Failure of follow-up of
abnormal cytology
106 (13%) 91 (7%)
Screening history of women with
invasive cervical carcinoma
1. Leyden WA, et al. J Natl Cancer Inst 2005; 97:675683;
2. Andrae B, et al. J Natl Cancer Inst 2008; 100:622629.
Results of the NTCC study
(Nuove Tecnologie per lo Screening
del Cancro Cervicale)
Setting: population based screening programme
Prospective randomized study on new screening test
Accrual phase: March 2002 to December 2004
94,370 women aged 25–60 years were randomized
Arm A 47,001 = conventional cytology
Arm B 47,369 = HPV testing (HC2)
Two screening rounds were completed (6 years)
METHODS
Women were divided into two different age
groups:
• 25 to 34
• 35 to 60
METHODS
The primary endpoint was the detection of
grade 2 and 3 CIN, and of invasive cervical
cancers during the first and second screening
rounds.
Analysis was done by intention to screen.
METHODS
Relative detection (HPV vs cytology) was:
• 2·00 for CIN2
• 2·08 for CIN3
• 2·03 for CIN2 and 3
RESULTS: first round, 35-60 yrs
Meaning:
HPV test detects 2 times more CIN 2-3 than pap
In other words the pap smear is negative in 50% of
CIN2-3
Relative detection (HPV vs cytology) was:
• 2·00 for CIN2
• 2·08 for CIN3
• 2·03 for CIN2 and 3
RESULTS: first round, 35-60 yrs
Question:
Are these “new” CIN2-3 clinically relevant?
Go to the second round…
RESULTS: second round, 35-60 yrs
Meaning:
In the HPV group the CIN2-3 were identified
earlier than in the cytology arm
the relative detection (HPV vs cytology) was
• 0·54 for CIN2,
• 0·48 for CIN3
• 0·51 for CIN2 and 3
RESULTS: second round, 35-60 yrs
Question:
Which is the clincal value of the “anticipated”
diagnosis?
the relative detection (HPV vs cytology) was
• 0·54 for CIN2,
• 0·48 for CIN3
• 0·51 for CIN2 and 3
RESULTS: 35-60 yrs
Question:
Which is the clincal value of the “anticipated”
diagnosis?
It is safe to increase the intervals between two
screens.
But what about the invasive cancers?
First Round 6 8 0.61
Second Round 0 7 0.016
Total 6 15 0.052
HPV test pap smear P value
RESULTS: 35-60 yrs
Number of invasive cancers
Meaning:
Follow up of untreated CIN2-3 carries the risk
of cancer development
First Round 6 8 0.61
Second Round 0 7 0.016
Total 6 15 0.052
HPV test pap smear P value
RESULTS: 35-60 yrs
Number of invasive cancers
Clinical consequences of the study:
Stop pap smear screening and switch to HPV
testing
Relative detection (HPV vs cytology) round one
• 2·00 for CIN2
• 2·08 for CIN3
• 2·03 for CIN2 and 3 together.
Relative detection (HPV vs cytology) at round two
• 0·54 for CIN2
• 0·48 for CIN3
• 0·51 for CIN2 and 3 together.
RESULTS: 35-60 yrs
HPV testing:
•Reassure more than 90% of negative women
(negative is negative; interval increase)
•Offer better protection against cancer
RESULTS: 25-34 yrs
What about the young women,
aged 25 to 34?
Same results or different situation?
RESULTS: 25-34 yrs
The relative detection (HPV vs cytology) was:
Round 1
• 3·91 for CIN3 and AIS
Round two
• 0·20 for CIN3 and AIS.
Meaning:
Four times more CIN3 and AIS detected by
HPV testing
Five times less CIN3 and AIS in the subsequent
round (more evident effect in young women
than in older)
First Round 1 1 1.00
Second Round 0 2 0.50
Total 1 3 0.37
HPV test pap smear P value
RESULTS: 25-34 yrs
Number of invasive cancers
Clinical consequences of the study:
Some considerations….
RESULTS: 25-34 yrs
The relative detection (HPV vs cytology) was:
Round 1
• 3·91 for CIN3 and AIS
Round two
• 0·20 for CIN3 and AIS.
Considerations:
Double number of lesions in the whole period
(overdiagnosis-overtreatment)
First Round 1 1 1.00
Second Round 0 2 0.50
Total 1 3 0.37
HPV test pap smear P value
RESULTS: 25-34 yrs
Number of invasive cancers
Clinical consequences of the data 25-34 yrs:
The increment in cancer detection is counter balanced by an
increase in diagnosis and treatment of clinically non relevant
(regressing?) CIN2-3
First Round 7 9 0.62
Second Round 0 9 0.004
Total 7 18 0.028
HPV test pap smear P value
RESULTS: 25-60 yrs
Number of invasive cancers
The total figures of cancer reduction is still
impressive; this figure prompted GISCi to start
the long and difficult process to abandon pap
smear as primary screening test because it is
unethical to continue with pap smear screening
HPV TEST:
Which optimal use?
• HPV test has an high NPV
• HPV test is ideally suited to reassure the
negative HPV individuals and to increase
intervals between two subsequent screens
• at any age HPV negative test is reassuring
There are no scientific doubt
that HPV test should be used as
primary screening test.
Implementation is still a
problem where pap smear
screening system is in place
CONCLUSIONS
It is a Copernican revolution…
Copernicus was placed under investigation…..
1940’ TECHNOLOGY
THANK YOU FOR YOUR
ATTENTION!
Mario Sideri
Unità Ginecologia Preventiva
Istituto Europeo di Oncologia, Milano
Italian HPV Study Group (IHSG)

More Related Content

What's hot

4 prof james bently management guidelines 2014
4  prof james bently management guidelines 20144  prof james bently management guidelines 2014
4 prof james bently management guidelines 2014Tariq Mohammed
 
Treatment of cin2 and persisten c in1
Treatment of cin2 and persisten c in1Treatment of cin2 and persisten c in1
Treatment of cin2 and persisten c in1Debbie Lewis
 
The international federation for cervical pathology and colposcopy course
The international federation for cervical pathology and colposcopy courseThe international federation for cervical pathology and colposcopy course
The international federation for cervical pathology and colposcopy courseTariq Mohammed
 
Cervical cancer screening module 3
Cervical cancer screening module 3Cervical cancer screening module 3
Cervical cancer screening module 3MMSCME
 
Uses of HPV Testing in Triage of cervical Screening
Uses of HPV Testing in Triage of cervical ScreeningUses of HPV Testing in Triage of cervical Screening
Uses of HPV Testing in Triage of cervical ScreeningDr Dirk Grothuesmann
 
4 prof walter managmet of cin
4  prof walter managmet of cin4  prof walter managmet of cin
4 prof walter managmet of cinTariq Mohammed
 
Asccp management guidelines august 2014 ppt. Dr. Sharda Jain /Dr Jyoti Agarw...
Asccp management guidelines august 2014 ppt.  Dr. Sharda Jain /Dr Jyoti Agarw...Asccp management guidelines august 2014 ppt.  Dr. Sharda Jain /Dr Jyoti Agarw...
Asccp management guidelines august 2014 ppt. Dr. Sharda Jain /Dr Jyoti Agarw...Lifecare Centre
 
Cervical Screening State of the Art 2016
Cervical Screening State of the Art 2016Cervical Screening State of the Art 2016
Cervical Screening State of the Art 2016Dr Dirk Grothuesmann
 
5 prof james bently mgmt genital hpv 2014
5  prof james bently mgmt genital hpv 20145  prof james bently mgmt genital hpv 2014
5 prof james bently mgmt genital hpv 2014Tariq Mohammed
 
Minor abnormalities
Minor abnormalitiesMinor abnormalities
Minor abnormalitiesDebbie Lewis
 
Cervical cancer - Role of screening and management of advanced stage cervical...
Cervical cancer - Role of screening and management of advanced stage cervical...Cervical cancer - Role of screening and management of advanced stage cervical...
Cervical cancer - Role of screening and management of advanced stage cervical...Alok Gupta
 
Basics To Ca Cx Screening (Eastern Biotech)
Basics To Ca Cx Screening (Eastern Biotech)Basics To Ca Cx Screening (Eastern Biotech)
Basics To Ca Cx Screening (Eastern Biotech)Pankaj Sohaney
 
Cervical cancer screening guidelines 2013
Cervical cancer screening guidelines 2013Cervical cancer screening guidelines 2013
Cervical cancer screening guidelines 2013Lifecare Centre
 
Rev4.hpv dna testing for s2011
Rev4.hpv dna testing for s2011Rev4.hpv dna testing for s2011
Rev4.hpv dna testing for s2011Tariq Mohammed
 
Khalid sait saudi belgium seminal march 18 2014
Khalid sait saudi  belgium seminal march 18 2014Khalid sait saudi  belgium seminal march 18 2014
Khalid sait saudi belgium seminal march 18 2014Tariq Mohammed
 
Screening for cervical cancer
Screening for  cervical cancerScreening for  cervical cancer
Screening for cervical cancerAboubakr Elnashar
 

What's hot (20)

4 prof james bently management guidelines 2014
4  prof james bently management guidelines 20144  prof james bently management guidelines 2014
4 prof james bently management guidelines 2014
 
Treatment of cin2 and persisten c in1
Treatment of cin2 and persisten c in1Treatment of cin2 and persisten c in1
Treatment of cin2 and persisten c in1
 
The international federation for cervical pathology and colposcopy course
The international federation for cervical pathology and colposcopy courseThe international federation for cervical pathology and colposcopy course
The international federation for cervical pathology and colposcopy course
 
Asccp colposcopy standards___role_of_colposcopy,.3
Asccp colposcopy standards___role_of_colposcopy,.3Asccp colposcopy standards___role_of_colposcopy,.3
Asccp colposcopy standards___role_of_colposcopy,.3
 
Cervical cancer screening module 3
Cervical cancer screening module 3Cervical cancer screening module 3
Cervical cancer screening module 3
 
Uses of HPV Testing in Triage of cervical Screening
Uses of HPV Testing in Triage of cervical ScreeningUses of HPV Testing in Triage of cervical Screening
Uses of HPV Testing in Triage of cervical Screening
 
4 prof walter managmet of cin
4  prof walter managmet of cin4  prof walter managmet of cin
4 prof walter managmet of cin
 
Asccp management guidelines august 2014 ppt. Dr. Sharda Jain /Dr Jyoti Agarw...
Asccp management guidelines august 2014 ppt.  Dr. Sharda Jain /Dr Jyoti Agarw...Asccp management guidelines august 2014 ppt.  Dr. Sharda Jain /Dr Jyoti Agarw...
Asccp management guidelines august 2014 ppt. Dr. Sharda Jain /Dr Jyoti Agarw...
 
Cervical Screening State of the Art 2016
Cervical Screening State of the Art 2016Cervical Screening State of the Art 2016
Cervical Screening State of the Art 2016
 
5 prof james bently mgmt genital hpv 2014
5  prof james bently mgmt genital hpv 20145  prof james bently mgmt genital hpv 2014
5 prof james bently mgmt genital hpv 2014
 
Minor abnormalities
Minor abnormalitiesMinor abnormalities
Minor abnormalities
 
Cervical cancer - Role of screening and management of advanced stage cervical...
Cervical cancer - Role of screening and management of advanced stage cervical...Cervical cancer - Role of screening and management of advanced stage cervical...
Cervical cancer - Role of screening and management of advanced stage cervical...
 
Pap maneg
Pap manegPap maneg
Pap maneg
 
Cervical cancer screening
Cervical cancer screening Cervical cancer screening
Cervical cancer screening
 
Basics To Ca Cx Screening (Eastern Biotech)
Basics To Ca Cx Screening (Eastern Biotech)Basics To Ca Cx Screening (Eastern Biotech)
Basics To Ca Cx Screening (Eastern Biotech)
 
Cervical cancer screening guidelines 2013
Cervical cancer screening guidelines 2013Cervical cancer screening guidelines 2013
Cervical cancer screening guidelines 2013
 
Rev4.hpv dna testing for s2011
Rev4.hpv dna testing for s2011Rev4.hpv dna testing for s2011
Rev4.hpv dna testing for s2011
 
Khalid sait saudi belgium seminal march 18 2014
Khalid sait saudi  belgium seminal march 18 2014Khalid sait saudi  belgium seminal march 18 2014
Khalid sait saudi belgium seminal march 18 2014
 
HPV and Cervical Cancer Screening
HPV and Cervical Cancer ScreeningHPV and Cervical Cancer Screening
HPV and Cervical Cancer Screening
 
Screening for cervical cancer
Screening for  cervical cancerScreening for  cervical cancer
Screening for cervical cancer
 

Viewers also liked

Anatomical changes alzheimers transgenics
Anatomical changes alzheimers transgenicsAnatomical changes alzheimers transgenics
Anatomical changes alzheimers transgenicsAdam Bogart
 
Human Papiiloma Virus
Human Papiiloma VirusHuman Papiiloma Virus
Human Papiiloma Virusahmedicine
 
Cervical Cancer Screening - HPV - www.jinekolojivegebelik.com
Cervical Cancer Screening - HPV - www.jinekolojivegebelik.comCervical Cancer Screening - HPV - www.jinekolojivegebelik.com
Cervical Cancer Screening - HPV - www.jinekolojivegebelik.comjinekolojivegebelik.com
 
Molecular tests to detect human papillomavirus
Molecular tests to detect human papillomavirusMolecular tests to detect human papillomavirus
Molecular tests to detect human papillomavirusTariq Mohammed
 
Chame a atenção de recrutadores com o título do seu perfil
Chame a atenção de recrutadores com o título do seu perfil Chame a atenção de recrutadores com o título do seu perfil
Chame a atenção de recrutadores com o título do seu perfil Luciane Borges
 

Viewers also liked (8)

Anatomical changes alzheimers transgenics
Anatomical changes alzheimers transgenicsAnatomical changes alzheimers transgenics
Anatomical changes alzheimers transgenics
 
Human Papiiloma Virus
Human Papiiloma VirusHuman Papiiloma Virus
Human Papiiloma Virus
 
Hpv
HpvHpv
Hpv
 
Cervical Cancer Screening - HPV - www.jinekolojivegebelik.com
Cervical Cancer Screening - HPV - www.jinekolojivegebelik.comCervical Cancer Screening - HPV - www.jinekolojivegebelik.com
Cervical Cancer Screening - HPV - www.jinekolojivegebelik.com
 
Cervical cancer
Cervical cancerCervical cancer
Cervical cancer
 
Molecular tests to detect human papillomavirus
Molecular tests to detect human papillomavirusMolecular tests to detect human papillomavirus
Molecular tests to detect human papillomavirus
 
Chame a atenção de recrutadores com o título do seu perfil
Chame a atenção de recrutadores com o título do seu perfil Chame a atenção de recrutadores com o título do seu perfil
Chame a atenção de recrutadores com o título do seu perfil
 
H P V
H P VH P V
H P V
 

Similar to 1 dr mario sideri

Dr Ayman Ewies - Cervical screening 2009
Dr Ayman Ewies - Cervical screening 2009Dr Ayman Ewies - Cervical screening 2009
Dr Ayman Ewies - Cervical screening 2009AymanEwies
 
Future cervical screening program
Future cervical screening programFuture cervical screening program
Future cervical screening programDonald Angstetra
 
РREMALIGNANT AND MALIGNANT DISORDERS OF THE CERVIX.pdf
РREMALIGNANT AND MALIGNANT DISORDERS OF THE CERVIX.pdfРREMALIGNANT AND MALIGNANT DISORDERS OF THE CERVIX.pdf
РREMALIGNANT AND MALIGNANT DISORDERS OF THE CERVIX.pdfSyazwaniPiti
 
201405724 american-cancer-society
201405724 american-cancer-society201405724 american-cancer-society
201405724 american-cancer-societyhomeworkping4
 
Michael Marco ID Epi class slides on HPV Natural History
Michael Marco ID Epi class slides on HPV Natural HistoryMichael Marco ID Epi class slides on HPV Natural History
Michael Marco ID Epi class slides on HPV Natural Historymikemarco
 
Vulvar and vaginal cancer epidemiology and molecular pathogenesis
Vulvar and vaginal cancer epidemiology and molecular pathogenesisVulvar and vaginal cancer epidemiology and molecular pathogenesis
Vulvar and vaginal cancer epidemiology and molecular pathogenesisSravanthi Nuthalapati
 
Cervical cancer screening modalities
Cervical cancer screening modalitiesCervical cancer screening modalities
Cervical cancer screening modalitieschaimingcheng
 
1- prof james bently - hpv and vaccine jeddah 2015
 1- prof james bently - hpv and vaccine jeddah 2015 1- prof james bently - hpv and vaccine jeddah 2015
1- prof james bently - hpv and vaccine jeddah 2015Basalama Ali
 
Multipex for papillomavirus
Multipex for papillomavirusMultipex for papillomavirus
Multipex for papillomavirusPathKind Labs
 
Update on Cervical Cancer Screening Barb Apgar.ppt
Update on Cervical Cancer Screening Barb Apgar.pptUpdate on Cervical Cancer Screening Barb Apgar.ppt
Update on Cervical Cancer Screening Barb Apgar.pptSyedaAyeshaFatima2
 
Cervical cancer hpv-feb07
Cervical cancer hpv-feb07Cervical cancer hpv-feb07
Cervical cancer hpv-feb07Ules Abraham
 
Qick review for resedent nisrin
Qick review for resedent nisrinQick review for resedent nisrin
Qick review for resedent nisrinTariq Mohammed
 
CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)
CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)
CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)Mauricio Lema
 
Pap smear test
Pap smear testPap smear test
Pap smear testiangould64
 
Cervcal cancer prevention in sa
Cervcal cancer prevention in saCervcal cancer prevention in sa
Cervcal cancer prevention in saTariq Mohammed
 

Similar to 1 dr mario sideri (20)

Human papiloma virus
Human papiloma virusHuman papiloma virus
Human papiloma virus
 
Dr Ayman Ewies - Cervical screening 2009
Dr Ayman Ewies - Cervical screening 2009Dr Ayman Ewies - Cervical screening 2009
Dr Ayman Ewies - Cervical screening 2009
 
Future cervical screening program
Future cervical screening programFuture cervical screening program
Future cervical screening program
 
РREMALIGNANT AND MALIGNANT DISORDERS OF THE CERVIX.pdf
РREMALIGNANT AND MALIGNANT DISORDERS OF THE CERVIX.pdfРREMALIGNANT AND MALIGNANT DISORDERS OF THE CERVIX.pdf
РREMALIGNANT AND MALIGNANT DISORDERS OF THE CERVIX.pdf
 
Khartoum feb 2008
Khartoum feb 2008Khartoum feb 2008
Khartoum feb 2008
 
201405724 american-cancer-society
201405724 american-cancer-society201405724 american-cancer-society
201405724 american-cancer-society
 
Michael Marco ID Epi class slides on HPV Natural History
Michael Marco ID Epi class slides on HPV Natural HistoryMichael Marco ID Epi class slides on HPV Natural History
Michael Marco ID Epi class slides on HPV Natural History
 
Vulvar and vaginal cancer epidemiology and molecular pathogenesis
Vulvar and vaginal cancer epidemiology and molecular pathogenesisVulvar and vaginal cancer epidemiology and molecular pathogenesis
Vulvar and vaginal cancer epidemiology and molecular pathogenesis
 
Cervical cancer screening modalities
Cervical cancer screening modalitiesCervical cancer screening modalities
Cervical cancer screening modalities
 
1- prof james bently - hpv and vaccine jeddah 2015
 1- prof james bently - hpv and vaccine jeddah 2015 1- prof james bently - hpv and vaccine jeddah 2015
1- prof james bently - hpv and vaccine jeddah 2015
 
Multipex for papillomavirus
Multipex for papillomavirusMultipex for papillomavirus
Multipex for papillomavirus
 
Update on Cervical Cancer Screening Barb Apgar.ppt
Update on Cervical Cancer Screening Barb Apgar.pptUpdate on Cervical Cancer Screening Barb Apgar.ppt
Update on Cervical Cancer Screening Barb Apgar.ppt
 
Cervical cancer hpv-feb07
Cervical cancer hpv-feb07Cervical cancer hpv-feb07
Cervical cancer hpv-feb07
 
Cervical cancer
Cervical cancer Cervical cancer
Cervical cancer
 
Qick review for resedent nisrin
Qick review for resedent nisrinQick review for resedent nisrin
Qick review for resedent nisrin
 
CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)
CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)
CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)
 
Pap smear test
Pap smear testPap smear test
Pap smear test
 
Cervcal cancer prevention in sa
Cervcal cancer prevention in saCervcal cancer prevention in sa
Cervcal cancer prevention in sa
 
HPV Prevention for Cancer Survivors
HPV Prevention for Cancer SurvivorsHPV Prevention for Cancer Survivors
HPV Prevention for Cancer Survivors
 
Cervical ca prevention
Cervical ca preventionCervical ca prevention
Cervical ca prevention
 

More from Tariq Mohammed

مؤسسة سالم بن محفوظ الخيرية عرض تعريفي مختصر 2017
مؤسسة سالم بن محفوظ الخيرية عرض تعريفي مختصر 2017مؤسسة سالم بن محفوظ الخيرية عرض تعريفي مختصر 2017
مؤسسة سالم بن محفوظ الخيرية عرض تعريفي مختصر 2017Tariq Mohammed
 
Gari et al bmc medical genetics
Gari et al bmc medical geneticsGari et al bmc medical genetics
Gari et al bmc medical geneticsTariq Mohammed
 
ألعلاج الكيماوي
ألعلاج الكيماويألعلاج الكيماوي
ألعلاج الكيماويTariq Mohammed
 
The international federation for cervical pathology and colposcopy course
The international federation for cervical pathology and colposcopy courseThe international federation for cervical pathology and colposcopy course
The international federation for cervical pathology and colposcopy courseTariq Mohammed
 
The international federation for cervical pathology and colposcopy course
The international federation for cervical pathology and colposcopy courseThe international federation for cervical pathology and colposcopy course
The international federation for cervical pathology and colposcopy courseTariq Mohammed
 
بطاقة الدعوة
بطاقة الدعوةبطاقة الدعوة
بطاقة الدعوةTariq Mohammed
 
1 prof james bently cervical cancer screening 2014
1  prof james bently cervical cancer screening 20141  prof james bently cervical cancer screening 2014
1 prof james bently cervical cancer screening 2014Tariq Mohammed
 
1 prof walter colposcopy jan14
1  prof walter colposcopy jan14 1  prof walter colposcopy jan14
1 prof walter colposcopy jan14 Tariq Mohammed
 
Prof khalid sait vlvar dermatosis ifcpc 2014
Prof khalid sait vlvar dermatosis ifcpc 2014Prof khalid sait vlvar dermatosis ifcpc 2014
Prof khalid sait vlvar dermatosis ifcpc 2014Tariq Mohammed
 
Poster nisreen anfanan
Poster nisreen anfananPoster nisreen anfanan
Poster nisreen anfananTariq Mohammed
 

More from Tariq Mohammed (18)

مؤسسة سالم بن محفوظ الخيرية عرض تعريفي مختصر 2017
مؤسسة سالم بن محفوظ الخيرية عرض تعريفي مختصر 2017مؤسسة سالم بن محفوظ الخيرية عرض تعريفي مختصر 2017
مؤسسة سالم بن محفوظ الخيرية عرض تعريفي مختصر 2017
 
عرض تقديمي1
عرض تقديمي1عرض تقديمي1
عرض تقديمي1
 
Stem cell research
Stem cell researchStem cell research
Stem cell research
 
How did it all start
How did it all startHow did it all start
How did it all start
 
Icrs poster 2
Icrs poster  2Icrs poster  2
Icrs poster 2
 
Gari et al bmc medical genetics
Gari et al bmc medical geneticsGari et al bmc medical genetics
Gari et al bmc medical genetics
 
Fphys 07-00180
Fphys 07-00180Fphys 07-00180
Fphys 07-00180
 
ألعلاج الكيماوي
ألعلاج الكيماويألعلاج الكيماوي
ألعلاج الكيماوي
 
The international federation for cervical pathology and colposcopy course
The international federation for cervical pathology and colposcopy courseThe international federation for cervical pathology and colposcopy course
The international federation for cervical pathology and colposcopy course
 
The international federation for cervical pathology and colposcopy course
The international federation for cervical pathology and colposcopy courseThe international federation for cervical pathology and colposcopy course
The international federation for cervical pathology and colposcopy course
 
Public lecture
Public lecturePublic lecture
Public lecture
 
بطاقة الدعوة
بطاقة الدعوةبطاقة الدعوة
بطاقة الدعوة
 
2 dr mario sideri vv
2  dr mario sideri  vv2  dr mario sideri  vv
2 dr mario sideri vv
 
1 prof james bently cervical cancer screening 2014
1  prof james bently cervical cancer screening 20141  prof james bently cervical cancer screening 2014
1 prof james bently cervical cancer screening 2014
 
1 prof walter colposcopy jan14
1  prof walter colposcopy jan14 1  prof walter colposcopy jan14
1 prof walter colposcopy jan14
 
Prof khalid sait vlvar dermatosis ifcpc 2014
Prof khalid sait vlvar dermatosis ifcpc 2014Prof khalid sait vlvar dermatosis ifcpc 2014
Prof khalid sait vlvar dermatosis ifcpc 2014
 
2 prof walter culture
2  prof walter culture2  prof walter culture
2 prof walter culture
 
Poster nisreen anfanan
Poster nisreen anfananPoster nisreen anfanan
Poster nisreen anfanan
 

Recently uploaded

Behavioral Disorder: Schizophrenia & it's Case Study.pdf
Behavioral Disorder: Schizophrenia & it's Case Study.pdfBehavioral Disorder: Schizophrenia & it's Case Study.pdf
Behavioral Disorder: Schizophrenia & it's Case Study.pdfSELF-EXPLANATORY
 
Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |
Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |
Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |aasikanpl
 
Cultivation of KODO MILLET . made by Ghanshyam pptx
Cultivation of KODO MILLET . made by Ghanshyam pptxCultivation of KODO MILLET . made by Ghanshyam pptx
Cultivation of KODO MILLET . made by Ghanshyam pptxpradhanghanshyam7136
 
VIRUSES structure and classification ppt by Dr.Prince C P
VIRUSES structure and classification ppt by Dr.Prince C PVIRUSES structure and classification ppt by Dr.Prince C P
VIRUSES structure and classification ppt by Dr.Prince C PPRINCE C P
 
Boyles law module in the grade 10 science
Boyles law module in the grade 10 scienceBoyles law module in the grade 10 science
Boyles law module in the grade 10 sciencefloriejanemacaya1
 
Grafana in space: Monitoring Japan's SLIM moon lander in real time
Grafana in space: Monitoring Japan's SLIM moon lander  in real timeGrafana in space: Monitoring Japan's SLIM moon lander  in real time
Grafana in space: Monitoring Japan's SLIM moon lander in real timeSatoshi NAKAHIRA
 
Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)PraveenaKalaiselvan1
 
Animal Communication- Auditory and Visual.pptx
Animal Communication- Auditory and Visual.pptxAnimal Communication- Auditory and Visual.pptx
Animal Communication- Auditory and Visual.pptxUmerFayaz5
 
GFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxGFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxAleenaTreesaSaji
 
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptxSOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptxkessiyaTpeter
 
Biopesticide (2).pptx .This slides helps to know the different types of biop...
Biopesticide (2).pptx  .This slides helps to know the different types of biop...Biopesticide (2).pptx  .This slides helps to know the different types of biop...
Biopesticide (2).pptx .This slides helps to know the different types of biop...RohitNehra6
 
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...Sérgio Sacani
 
Luciferase in rDNA technology (biotechnology).pptx
Luciferase in rDNA technology (biotechnology).pptxLuciferase in rDNA technology (biotechnology).pptx
Luciferase in rDNA technology (biotechnology).pptxAleenaTreesaSaji
 
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.aasikanpl
 
Isotopic evidence of long-lived volcanism on Io
Isotopic evidence of long-lived volcanism on IoIsotopic evidence of long-lived volcanism on Io
Isotopic evidence of long-lived volcanism on IoSérgio Sacani
 
Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.aasikanpl
 
Nanoparticles synthesis and characterization​ ​
Nanoparticles synthesis and characterization​  ​Nanoparticles synthesis and characterization​  ​
Nanoparticles synthesis and characterization​ ​kaibalyasahoo82800
 
Analytical Profile of Coleus Forskohlii | Forskolin .pptx
Analytical Profile of Coleus Forskohlii | Forskolin .pptxAnalytical Profile of Coleus Forskohlii | Forskolin .pptx
Analytical Profile of Coleus Forskohlii | Forskolin .pptxSwapnil Therkar
 
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...Sérgio Sacani
 

Recently uploaded (20)

Behavioral Disorder: Schizophrenia & it's Case Study.pdf
Behavioral Disorder: Schizophrenia & it's Case Study.pdfBehavioral Disorder: Schizophrenia & it's Case Study.pdf
Behavioral Disorder: Schizophrenia & it's Case Study.pdf
 
Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |
Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |
Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |
 
Cultivation of KODO MILLET . made by Ghanshyam pptx
Cultivation of KODO MILLET . made by Ghanshyam pptxCultivation of KODO MILLET . made by Ghanshyam pptx
Cultivation of KODO MILLET . made by Ghanshyam pptx
 
VIRUSES structure and classification ppt by Dr.Prince C P
VIRUSES structure and classification ppt by Dr.Prince C PVIRUSES structure and classification ppt by Dr.Prince C P
VIRUSES structure and classification ppt by Dr.Prince C P
 
Boyles law module in the grade 10 science
Boyles law module in the grade 10 scienceBoyles law module in the grade 10 science
Boyles law module in the grade 10 science
 
Grafana in space: Monitoring Japan's SLIM moon lander in real time
Grafana in space: Monitoring Japan's SLIM moon lander  in real timeGrafana in space: Monitoring Japan's SLIM moon lander  in real time
Grafana in space: Monitoring Japan's SLIM moon lander in real time
 
Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)
 
Animal Communication- Auditory and Visual.pptx
Animal Communication- Auditory and Visual.pptxAnimal Communication- Auditory and Visual.pptx
Animal Communication- Auditory and Visual.pptx
 
GFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxGFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptx
 
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptxSOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
 
Biopesticide (2).pptx .This slides helps to know the different types of biop...
Biopesticide (2).pptx  .This slides helps to know the different types of biop...Biopesticide (2).pptx  .This slides helps to know the different types of biop...
Biopesticide (2).pptx .This slides helps to know the different types of biop...
 
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
 
Luciferase in rDNA technology (biotechnology).pptx
Luciferase in rDNA technology (biotechnology).pptxLuciferase in rDNA technology (biotechnology).pptx
Luciferase in rDNA technology (biotechnology).pptx
 
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
 
Isotopic evidence of long-lived volcanism on Io
Isotopic evidence of long-lived volcanism on IoIsotopic evidence of long-lived volcanism on Io
Isotopic evidence of long-lived volcanism on Io
 
Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
 
Nanoparticles synthesis and characterization​ ​
Nanoparticles synthesis and characterization​  ​Nanoparticles synthesis and characterization​  ​
Nanoparticles synthesis and characterization​ ​
 
Analytical Profile of Coleus Forskohlii | Forskolin .pptx
Analytical Profile of Coleus Forskohlii | Forskolin .pptxAnalytical Profile of Coleus Forskohlii | Forskolin .pptx
Analytical Profile of Coleus Forskohlii | Forskolin .pptx
 
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
 
The Philosophy of Science
The Philosophy of ScienceThe Philosophy of Science
The Philosophy of Science
 

1 dr mario sideri

  • 1. HPV NATURAL HISTORY AND HPV TESTING Mario Sideri Unità Ginecologia Preventiva Istituto Europeo di Oncologia, Milano Italian HPV Study Group (IHSG)
  • 2. What’s new? In the last 30 years the causal association between HPV infection and cervical cancer has been demonstrated papillomavirus
  • 3. The Nobel Prize in Physiology or Medicine 2008 Harald Zur Hausen for his discovery of human Papilloma viruses causing cervical cancer
  • 4. Vaccination Population at risk (screening) Detection & Intervention (pre-cancer elimination) OLD STRATEGYNEW STRATEGY
  • 5. Papillomavirus is known from decades. However only in the recent years we have recognized the wide diffusion and the benign meaning of HPV infection What is HPV?
  • 7.  Papillomavirus are species specific viruses  HPV are very common viruses and are present in almost all the species of mammalians and birds  More than 100 HPV types have been described in humans  Human PV infect the skin and mucous membranes where they can cause typical benign proliferations as warts and papillomas Papillomavirus De Villiers et al., Virology (2004)
  • 8.  HPV infection causes in some instances microproliferations not visible with the naked eye  HPV tends to prersist for long periods of time, often as latent infection  Some HPV associated lesions can evolve into malignant neoplasia Papillomavirus De Villiers et al., Virology (2004)
  • 10.  90% of young women acquires the virus with the beginning of sexual intercourses  Most of them become negative after 6-18 months of transient infection  Only about 10% of young women become persistently infected with HPV for a longer period of time HPV natural history
  • 11.  less than 30% of persitently infected women develops a CIN lesion  the vast majority of CIN clears spontaneously  some CIN persist, but even most of persistent CIN3 will never become cancer HPV natural history
  • 12. In this way, the almost ubiquitary HPV infection, very rarely ends up into cervical cancer. Conversely, the association of HPV infection with cervical cancer offers unique opportunities of cancer prevention HPV and Cervical Cancer
  • 13.  553 college students (mean age 19)  HPV test and pap smear every 4 months for 5 years  mean follow up 41.2 months HPV natural history: Seattle Study Winer et al., Am J Epidemiol (2003)
  • 14.  19.7% was HPV DNA positive at enrollment  During two years follow up 39% of women negative at enrollment became HPV DNA positive  High risk HPV were found more frequently, types 16,18,51,56,33,35,39 Winer et al., Am J Epidemiol (2003) HPV natural history: Seattle Study
  • 15. Winer et al., Am J Epidemiol (2003)
  • 16.  60 adolescents (14-17) were followed for a mean time of 26 months  Every three months were evaluated for HPV infection  In addition a weekly self sampling for HPV was performed for a time lenght up to 15 weeks Brown et al., J Infect Dis (2005) HPV natural history: Adolescent study
  • 17. Timing HPV overall HPV oncogenic Enrollment 28% 22% Last visit 40% 37% At least once* 82% 77% Brown et al., J Infect Dis (2005) * At least two positive samples HPV natural history: Adolescent study
  • 18. Only 3 girls were always negative to vaginal HPV testing  All referred to be virgins Brown et al., J Infect Dis (2005) HPV natural history: Adolescent study
  • 19.  HPV detectability rarely persist for more than 24 months  in more than 90% of the cases HPV becomes undetectable within 24 months HPV Natural history
  • 20. Detectable HPV Author Age 6 12 24 __________________________________ Woodman 20 24 4 <1 Mosicki 20 50 30 10 Ho 20 30 9 % persistent HPV infection in months
  • 21.  persistent HPV infection may cause the development of invasive cervical cancer in 10 to 15 years  many known and unknown co-factors are responsible for cancer develpoment HPV Natural history
  • 22.  20.817 women with neagtive cytology at baseline  HPV test at enrollement  Follow up for 10 years; endpoint CIN2-3 development Natural history of HPV oncogenesis Portland study Kahn et al., JNCI (2005)
  • 23. 0% 5% 10% 15% 20% 25% 0,0 4,5 15,0 27,0 39,0 51,0 63,0 75,0 87,0 99,0 111,0 119,5 Follow-Up Time (months) CumulativeIncidenceRateof≥CIN3 HPV16 + HPV18 + HPV + HPV+/ HPV16- /18- HPV - Kahn et al., JNCI (2005) CIN3 develpoment during follow up in relation to HPV status
  • 24. ALL HPV 16 Rodriguez et al., Proceedings of 24th International HPV Conference and Clinical Workshop, China 2007. Abstract
  • 25.  HPV persistent infection can cause the development of invasive cervical cancer in 10 to 15 years  many co-factors are involved in the process of cancer development Natural history of HPV infection
  • 26. Few studies addressed in longitudinal studies HPV status in sex couples HPV: what we know in sex couples?
  • 27. ….In our current study, less than half of the couples exhibited perfect HPV- type specific concordance. More than one third of couples had complete discordance…..
  • 28. Multivariate regression analysis. Reporting a new sex partner or the same sex partner or no sex partner was not significantly associated with the risk of infection reappearance.
  • 31. HPV infection is very common and is not a disease pre-cancer is a rare event cancer is an exceptional event HPV: what we now know
  • 32. HPV infection is very rarely associated to cancer development However HPV is necessary for cancer develpoment HPV and Cervical Cancer
  • 33. Cervical cancer screening • Pap smear as primary screening test • Identification of CIN3 • Elimination of CIN3 through excisional conservative surgery The historical strategy
  • 34. Screening aim To identify and eliminate this lesion
  • 35.
  • 36. Vaccination Population at risk (screening) Detection & Intervention (pre-cancer elimination) USUAL STRATEGYNEW STRATEGY
  • 37. Cervical cancer screening • Testing the population for the causative agent of cervical cancer • Testing aimed to identifcation of CIN3 • Testing not aimed to detect infection HPV TESTING
  • 38. Cervical cancer screening PROOF of PRINCIPLE HPV TESTING
  • 39. CERVICAL CANCER SCREENING IN INDIA N = 131.476 Four arms randomized study: •Control •VIA •Pap smear •HPV test HPV test Pap smear VIA Control
  • 40.
  • 41. Cervical cancer screening known limitations of cytology screening PAP SMEAR
  • 42. 30 40 50 60 70 80 90 100 1971 1973 1975 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 8 9 10 11 12 13 14 15 16 17 18 Incidence/100000 ScreeningCoverage(%) Cervical cancer screening Start of organised screening
  • 43. Never pap smear 162 62% Pos. pap & adequate follow-up 29 11% False negative pap 37 14% Previous abnormal smear* 34 13% TOTAL 262 100% Screening “failures” italian data Amadori A. Int J Gynecol Cancer 1998 262 invasive cancer cases, TR Romagna and Toscana (1986-93). * Repeat smear not done, colposcopy not done, colposcopy done late, negative colposcopies, negative biopsies, CIN3 diagnosed with no further action.
  • 44. Cause, n (%) Kaiser study1 Swedish study2 No recent screen 464 (56%) 789 (64%) Cytology detection failure 263 (32%) 300 (24%) Failure of follow-up of abnormal cytology 106 (13%) 91 (7%) Screening history of women with invasive cervical carcinoma 1. Leyden WA, et al. J Natl Cancer Inst 2005; 97:675683; 2. Andrae B, et al. J Natl Cancer Inst 2008; 100:622629.
  • 45.
  • 46. Results of the NTCC study (Nuove Tecnologie per lo Screening del Cancro Cervicale)
  • 47. Setting: population based screening programme Prospective randomized study on new screening test Accrual phase: March 2002 to December 2004 94,370 women aged 25–60 years were randomized Arm A 47,001 = conventional cytology Arm B 47,369 = HPV testing (HC2) Two screening rounds were completed (6 years) METHODS
  • 48. Women were divided into two different age groups: • 25 to 34 • 35 to 60 METHODS
  • 49. The primary endpoint was the detection of grade 2 and 3 CIN, and of invasive cervical cancers during the first and second screening rounds. Analysis was done by intention to screen. METHODS
  • 50. Relative detection (HPV vs cytology) was: • 2·00 for CIN2 • 2·08 for CIN3 • 2·03 for CIN2 and 3 RESULTS: first round, 35-60 yrs Meaning: HPV test detects 2 times more CIN 2-3 than pap In other words the pap smear is negative in 50% of CIN2-3
  • 51. Relative detection (HPV vs cytology) was: • 2·00 for CIN2 • 2·08 for CIN3 • 2·03 for CIN2 and 3 RESULTS: first round, 35-60 yrs Question: Are these “new” CIN2-3 clinically relevant? Go to the second round…
  • 52. RESULTS: second round, 35-60 yrs Meaning: In the HPV group the CIN2-3 were identified earlier than in the cytology arm the relative detection (HPV vs cytology) was • 0·54 for CIN2, • 0·48 for CIN3 • 0·51 for CIN2 and 3
  • 53. RESULTS: second round, 35-60 yrs Question: Which is the clincal value of the “anticipated” diagnosis? the relative detection (HPV vs cytology) was • 0·54 for CIN2, • 0·48 for CIN3 • 0·51 for CIN2 and 3
  • 54. RESULTS: 35-60 yrs Question: Which is the clincal value of the “anticipated” diagnosis? It is safe to increase the intervals between two screens. But what about the invasive cancers?
  • 55. First Round 6 8 0.61 Second Round 0 7 0.016 Total 6 15 0.052 HPV test pap smear P value RESULTS: 35-60 yrs Number of invasive cancers Meaning: Follow up of untreated CIN2-3 carries the risk of cancer development
  • 56. First Round 6 8 0.61 Second Round 0 7 0.016 Total 6 15 0.052 HPV test pap smear P value RESULTS: 35-60 yrs Number of invasive cancers Clinical consequences of the study: Stop pap smear screening and switch to HPV testing
  • 57. Relative detection (HPV vs cytology) round one • 2·00 for CIN2 • 2·08 for CIN3 • 2·03 for CIN2 and 3 together. Relative detection (HPV vs cytology) at round two • 0·54 for CIN2 • 0·48 for CIN3 • 0·51 for CIN2 and 3 together. RESULTS: 35-60 yrs HPV testing: •Reassure more than 90% of negative women (negative is negative; interval increase) •Offer better protection against cancer
  • 58. RESULTS: 25-34 yrs What about the young women, aged 25 to 34? Same results or different situation?
  • 59. RESULTS: 25-34 yrs The relative detection (HPV vs cytology) was: Round 1 • 3·91 for CIN3 and AIS Round two • 0·20 for CIN3 and AIS. Meaning: Four times more CIN3 and AIS detected by HPV testing Five times less CIN3 and AIS in the subsequent round (more evident effect in young women than in older)
  • 60. First Round 1 1 1.00 Second Round 0 2 0.50 Total 1 3 0.37 HPV test pap smear P value RESULTS: 25-34 yrs Number of invasive cancers Clinical consequences of the study: Some considerations….
  • 61. RESULTS: 25-34 yrs The relative detection (HPV vs cytology) was: Round 1 • 3·91 for CIN3 and AIS Round two • 0·20 for CIN3 and AIS. Considerations: Double number of lesions in the whole period (overdiagnosis-overtreatment)
  • 62. First Round 1 1 1.00 Second Round 0 2 0.50 Total 1 3 0.37 HPV test pap smear P value RESULTS: 25-34 yrs Number of invasive cancers Clinical consequences of the data 25-34 yrs: The increment in cancer detection is counter balanced by an increase in diagnosis and treatment of clinically non relevant (regressing?) CIN2-3
  • 63. First Round 7 9 0.62 Second Round 0 9 0.004 Total 7 18 0.028 HPV test pap smear P value RESULTS: 25-60 yrs Number of invasive cancers The total figures of cancer reduction is still impressive; this figure prompted GISCi to start the long and difficult process to abandon pap smear as primary screening test because it is unethical to continue with pap smear screening
  • 64.
  • 65. HPV TEST: Which optimal use? • HPV test has an high NPV • HPV test is ideally suited to reassure the negative HPV individuals and to increase intervals between two subsequent screens • at any age HPV negative test is reassuring
  • 66.
  • 67. There are no scientific doubt that HPV test should be used as primary screening test. Implementation is still a problem where pap smear screening system is in place CONCLUSIONS It is a Copernican revolution… Copernicus was placed under investigation…..
  • 68.
  • 69.
  • 70.
  • 72. THANK YOU FOR YOUR ATTENTION! Mario Sideri Unità Ginecologia Preventiva Istituto Europeo di Oncologia, Milano Italian HPV Study Group (IHSG)